Yibing Yan

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Yibing Yan et al. · Nature · 2012 · 1.1K citations

Medicine, Cancer Biology, Oncology +16

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Tuba N. Gide, Camelia Quek, Alexander M. Menzies et al. · Cancer Cell · 2019 · 1K citations · Full text

Life Sciences, Immunology, Oncology +17

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al. · The Lancet Oncology · 2016 · 1K citations

Medicine, Oncology, Pharmacology +11

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess et al. · The Lancet Oncology · 2018 · 658 citations · Full text

Medicine, Dermatology, Oncology +14

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2020 · 650 citations

Pharmacy, Oncology, Pharmacotherapy +15